SAUHF:OTC-Straumann Holding AG (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 127.25

Change

-5.10 (-3.85)%

Market Cap

USD 20.49B

Volume

263.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company also offers dental implants and components made from titanium, titanium alloy, and ceramics; prosthetic elements made of ceramics, metal or polymer; clear aligners and made of polymer; and biomaterials for tissue generation. In addition, it provides restorative solutions comprising abutments and related parts, as well as milling elements. Further, it provides digital equipment comprising scanners, milling machines, and 3D printers; software licenses; and training and other miscellaneous products. The company provides its products to general dentists, specialists, and dental technicians and laboratories through a network of distribution subsidiaries and partners, and third-party distributors. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

+0.72 (+0.52%)

USD 126.80B
ESLOF EssilorLuxottica Société ano..

+2.79 (+1.00%)

USD 125.52B
HOCPF HOYA Corporation

-5.40 (-4.52%)

USD 43.54B
HOCPY Hoya Corp

-1.60 (-1.38%)

USD 41.79B
TRUMF Terumo Corporation

-1.87 (-9.44%)

USD 28.03B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 22.03B
CLPBY Coloplast A

+0.01 (+0.10%)

USD 21.79B
CLPBF Coloplast A/S

+4.25 (+4.61%)

USD 21.70B
SRTOY Sartorius Stedim Biotech S.A

+0.65 (+3.03%)

USD 21.56B
SUVPF Sartorius Aktiengesellschaft

N/A

USD 16.40B

ETFs Containing SAUHF

IDLB 0.00 % 0.00 %

N/A

N/A
FEQD:LSE Fidelity Europe Quality I.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.86% 60% D- 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.86% 58% F 49% F
Trailing 12 Months  
Capital Gain -4.56% 57% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.56% 54% F 47% F
Trailing 5 Years  
Capital Gain 50.52% 87% B+ 73% C
Dividend Return 18.08% 96% N/A 46% F
Total Return 68.60% 89% A- 72% C
Average Annual (5 Year Horizon)  
Capital Gain 7.35% 68% D+ 56% F
Dividend Return 7.85% 66% D+ 53% F
Total Return 0.50% 32% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 46.03% 42% F 51% F
Risk Adjusted Return 17.06% 73% C 57% F
Market Capitalization 20.49B 82% B 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.